SCHEMBL4710902

SCHEMBL4710902

COc1cc(OC)cc(C(F)C#N)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
GAA P10253 2/20 0.37
CYP1A1 P04798 3/20 0.37
CYP1B1 Q16678 3/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2E1 P05181 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C8 P10632 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2A6 P11509 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP4B1 P13584 2/20 0.36
CYP2B6 P20813 2/20 0.36
CYP3A5 P20815 2/20 0.36
CYP2A7 P20853 2/20 0.36
CYP3A7 P24462 2/20 0.36
CYP2F1 P24903 2/20 0.36
CYP2C18 P33260 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2J2 P51589 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7811164 0.89 KMT2A (0.36) ALDH1A1GAAPBRM1NQO2KMT2A
SCHEMBL28782471 0.81 KMT2A (0.45) ALDH1A1CYP3A4PDE4APDE4BPDE4C
SCHEMBL3628529 0.79 EPAS1 (0.41) ALDH1A1CYP1A1CYP1B1
SCHEMBL4713706 0.77 ALDH1A1 (0.48) ALDH1A1GAACYP1A1CYP1B1CYP1A2
SCHEMBL4716539 0.75 ALDH1A1 (0.46) ALDH1A1GAACYP1A1CYP1B1CYP1A2
SCHEMBL11854342 0.75 ALDH1A1 (0.46) ALDH1A1GAACYP1A1CYP1B1CYP3A4
SCHEMBL28360321 0.75 ALDH1A1 (0.58) ALDH1A1CYP1A1CYP1B1CYP1A2CYP2E1
SCHEMBL24094553 0.74 KDM4E (0.39) ALDH1A1GAACYP1A1CYP1B1PDE4A
SCHEMBL30340528 0.74 KDM4E (0.39) ALDH1A1GAACYP1A1CYP1B1PDE4A
SCHEMBL9493364 0.73 ALDH1A1 (0.44) ALDH1A1GAACYP1A1CYP1B1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307450-B1 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones WARNER LAMBERT CO (US) 2008-09-17 EP disclosed
US-7022711-B2 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones WARNER-LAMBERT COMPANY (US) 2006-04-04 US disclosed
US-20030220345-A1 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones HAMBY JAMES MARINO (US) 2003-11-27 US disclosed
EP-1307450-A2 2-(4-PYRDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO(2.3-D)PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY (US) 2003-05-07 EP disclosed
WO-2002012238-A2 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY (US) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220345-A1 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones FLT1, FLT4, MKI67 ALDH1A1 930/4885GAA 4172/4885CYP1A1 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.